Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB
[10] [14] Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation, which are generally mild to moderate and diminish over time
A meta-analysis of seven SURPASS clinical trials in participants with T2DM showed the hazard ratios comparing tirzepatide versus controls of 0.80 (95% CI, 0.57 1.11) for 4-MACE, 0.90 (95% CI, 0.50 1.61) for cardiovascular death, and 0.80 (95% CI, 0.51 1.25) for all-cause mortality (264)
"The underreported symptoms are leads that came from patients themselves, unprompted, and clinicians could potentially pay attention to them." This kind of large-scale data capture and interrogation is made possible by the latest AI models